patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_515809 | REC_0012001 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 23 | 8.6 | 72 | male | 1 | 50 | 4 | 6 | pembrolizumab 200 mg q3w | 8.8 | true | MSS | 2026-03-15T05:35:59.865666+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_832849 | REC_0012002 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 39 | 10.6 | 68 | female | 0 | 14 | 6.3 | 4 | entrectinib 600 mg daily | 10.5 | false | MSI-H | 2026-03-15T05:35:59.865900+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_303587 | REC_0012003 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 10.1 | 71 | female | 0 | 6 | 4.5 | 7 | sotorasib 960 mg daily | 18 | false | MSS | 2026-03-15T05:35:59.866140+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_988423 | REC_0012004 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 21 | 11.2 | 78 | female | 2 | 19 | 7 | 0 | alectinib 600 mg BID | 35.2 | false | MSI-H | 2026-03-15T05:35:59.866373+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_399578 | REC_0012005 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 13.5 | 74 | female | 1 | 12 | 6.8 | 5 | osimertinib 80 mg daily | 14.8 | true | MSI-H | 2026-03-15T05:35:59.866603+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_268346 | REC_0012006 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 29 | 13.5 | 53 | female | 0 | 11 | 5.9 | 2 | osimertinib 80 mg daily | 23.7 | false | MSI-H | 2026-03-15T05:35:59.866836+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_673910 | REC_0012007 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 28 | 11.2 | 75 | female | 2 | 20 | 6.1 | 2 | entrectinib 600 mg daily | 10.8 | false | MSI-H | 2026-03-15T05:35:59.867067+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_385610 | REC_0012008 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 14.3 | 62 | female | 1 | 9 | 7 | 8 | sotorasib 960 mg daily | 10.2 | true | MSS | 2026-03-15T05:35:59.867302+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_764596 | REC_0012009 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 18 | 16.6 | 75 | female | 2 | 8 | 6 | 2 | osimertinib 80 mg daily | 14.3 | true | MSS | 2026-03-15T05:35:59.867536+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_382526 | REC_0012010 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 24 | 11.4 | 68 | female | 0 | 17 | 5.5 | 2 | osimertinib 80 mg daily | 36.3 | false | MSS | 2026-03-15T05:35:59.867765+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_554581 | REC_0012011 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 30 | 12.2 | 60 | female | 0 | 21 | 5.9 | 5 | sotorasib 960 mg daily | 12 | true | MSI-H | 2026-03-15T05:35:59.868001+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_233565 | REC_0012012 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 17 | 3.8 | 73 | female | 0 | 25 | 5 | 6 | carboplatin + paclitaxel + pembrolizumab | 14.5 | false | MSS | 2026-03-15T05:35:59.868259+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_109527 | REC_0012013 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 25 | 9.6 | 66 | female | 1 | 20 | 7.8 | 1 | osimertinib 80 mg daily | 23.4 | false | MSS | 2026-03-15T05:35:59.868535+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_112387 | REC_0012014 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 8.3 | 65 | female | 0 | 24 | 4.2 | 7 | entrectinib 600 mg daily | 16.4 | false | MSS | 2026-03-15T05:35:59.868771+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_825306 | REC_0012015 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 26 | 12.1 | 46 | male | 0 | 15 | 7.3 | 0 | alectinib 600 mg BID | 44.3 | false | MSS | 2026-03-15T05:35:59.869010+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_951677 | REC_0012016 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 17 | 11.2 | 65 | male | 0 | 13 | 4.1 | 0 | alectinib 600 mg BID | 21.9 | true | MSS | 2026-03-15T05:35:59.869246+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_790988 | REC_0012017 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 29 | 15.7 | 68 | female | 1 | 22 | 4.5 | 5 | osimertinib 80 mg daily | 10.1 | false | MSI-H | 2026-03-15T05:35:59.869481+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_192104 | REC_0012018 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 29 | 9.6 | 52 | female | 0 | 12 | 6.3 | 5 | entrectinib 600 mg daily | 6.5 | false | MSS | 2026-03-15T05:35:59.869710+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_616939 | REC_0012019 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 21 | 13.3 | 79 | female | 2 | 10 | 6.4 | 1 | osimertinib 80 mg daily | 10.8 | false | MSS | 2026-03-15T05:35:59.869943+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_493178 | REC_0012020 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 13.6 | 80 | female | 0 | 16 | 3 | 8 | entrectinib 600 mg daily | 17.3 | false | MSS | 2026-03-15T05:35:59.870175+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_499857 | REC_0012021 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 20 | 7.6 | 73 | female | 1 | 43 | 5.6 | 5 | carboplatin + paclitaxel + pembrolizumab | 18.3 | false | MSS | 2026-03-15T05:35:59.870402+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_753731 | REC_0012022 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 17.9 | 75 | male | 1 | 20 | 6.1 | 5 | entrectinib 600 mg daily | 11.7 | true | MSI-H | 2026-03-15T05:35:59.870638+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_200692 | REC_0012023 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 18 | 16.9 | 72 | female | 1 | 20 | 6.9 | 5 | sotorasib 960 mg daily | 11.3 | false | MSS | 2026-03-15T05:35:59.870870+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_597099 | REC_0012024 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 13.5 | 62 | female | 1 | 7 | 7 | 4 | entrectinib 600 mg daily | 14.8 | true | MSI-H | 2026-03-15T05:35:59.871104+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_508544 | REC_0012025 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 23 | 17.3 | 71 | female | 1 | 11 | 6 | 2 | entrectinib 600 mg daily | 19.6 | true | MSS | 2026-03-15T05:35:59.871338+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_952524 | REC_0012026 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 11.7 | 73 | female | 1 | 7 | 5.9 | 6 | osimertinib 80 mg daily | 13.6 | true | MSI-H | 2026-03-15T05:35:59.871610+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_436185 | REC_0012027 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 15.5 | 80 | female | 1 | 4 | 4.6 | 6 | sotorasib 960 mg daily | 15.5 | false | MSS | 2026-03-15T05:35:59.871844+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_486671 | REC_0012028 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 7.6 | 73 | female | 2 | 15 | 7 | 4 | osimertinib 80 mg daily | 8.6 | true | MSS | 2026-03-15T05:35:59.872094+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_818978 | REC_0012029 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 14 | 13.2 | 64 | female | 1 | 7 | 6.3 | 2 | alectinib 600 mg BID | 8.2 | false | MSI-H | 2026-03-15T05:35:59.872336+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_233919 | REC_0012030 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 34 | 5.4 | 66 | female | 0 | 13 | 3.3 | 4 | pembrolizumab 200 mg q3w | 10.4 | true | MSS | 2026-03-15T05:35:59.872564+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_796838 | REC_0012031 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 15.2 | 56 | male | 0 | 18 | 6 | 8 | sotorasib 960 mg daily | 6.6 | false | MSI-H | 2026-03-15T05:35:59.872803+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_905277 | REC_0012032 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 5.1 | 68 | female | 1 | 66 | 5.8 | 7 | carboplatin + paclitaxel + pembrolizumab | 11.7 | false | MSS | 2026-03-15T05:35:59.873035+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_196224 | REC_0012033 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 21 | 10.6 | 61 | female | 1 | 4 | 6.9 | 7 | entrectinib 600 mg daily | 7.1 | false | MSS | 2026-03-15T05:35:59.873272+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_359467 | REC_0012034 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 28 | 12.1 | 58 | female | 0 | 16 | 4.6 | 5 | pembrolizumab 200 mg q3w | 13.6 | true | MSI-H | 2026-03-15T05:35:59.873507+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_828722 | REC_0012035 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 11.8 | 52 | female | 0 | 16 | 5.2 | 8 | entrectinib 600 mg daily | 4 | false | MSS | 2026-03-15T05:35:59.873740+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_610541 | REC_0012036 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 28 | 7.4 | 81 | female | 2 | 38 | 6.9 | 4 | carboplatin + paclitaxel + pembrolizumab | 10.8 | true | MSS | 2026-03-15T05:35:59.873965+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_344003 | REC_0012037 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 22 | 6.7 | 60 | male | 0 | 17 | 4.1 | 10 | pembrolizumab 200 mg q3w | 10.7 | true | MSS | 2026-03-15T05:35:59.874198+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_736928 | REC_0012038 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 24 | 10.2 | 78 | female | 1 | 15 | 4.4 | 1 | pembrolizumab 200 mg q3w | 15.4 | true | MSI-H | 2026-03-15T05:35:59.874427+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_204077 | REC_0012039 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 30 | 20.9 | 74 | female | 1 | 24 | 3.4 | 7 | alectinib 600 mg BID | 9 | true | MSS | 2026-03-15T05:35:59.874702+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_680193 | REC_0012040 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 8.1 | 73 | female | 0 | 58 | 5 | 5 | carboplatin + paclitaxel + pembrolizumab | 7.2 | true | MSS | 2026-03-15T05:35:59.874941+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_993593 | REC_0012041 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 9.8 | 73 | male | 1 | 10 | 4.6 | 5 | osimertinib 80 mg daily | 11.9 | true | MSS | 2026-03-15T05:35:59.875172+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_371336 | REC_0012042 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 37 | 13.8 | 71 | female | 2 | 16 | 6.1 | 0 | sotorasib 960 mg daily | 16 | true | MSI-H | 2026-03-15T05:35:59.875409+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_209801 | REC_0012043 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 11.6 | 65 | male | 0 | 26 | 2.4 | 5 | sotorasib 960 mg daily | 13 | true | MSI-H | 2026-03-15T05:35:59.875644+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_216126 | REC_0012044 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 26 | 9.5 | 72 | female | 2 | 11 | 6.3 | 5 | pembrolizumab 200 mg q3w | 7.5 | false | MSS | 2026-03-15T05:35:59.875873+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_884873 | REC_0012045 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 8.8 | 65 | female | 1 | 54 | 6.2 | 7 | carboplatin + paclitaxel + pembrolizumab | 12 | false | MSS | 2026-03-15T05:35:59.876218+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_433166 | REC_0012046 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 19 | 2.9 | 63 | female | 0 | 8 | 6 | 2 | entrectinib 600 mg daily | 20.4 | false | MSS | 2026-03-15T05:35:59.876470+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_444455 | REC_0012047 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 35 | 16.8 | 83 | female | 1 | 22 | 4.7 | 5 | alectinib 600 mg BID | 5.7 | true | MSS | 2026-03-15T05:35:59.876707+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_374287 | REC_0012048 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 27 | 14.3 | 81 | female | 1 | 4 | 6.4 | 0 | sotorasib 960 mg daily | 38.9 | false | MSI-H | 2026-03-15T05:35:59.876938+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_165997 | REC_0012049 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 18 | 16.3 | 70 | female | 1 | 17 | 6 | 2 | osimertinib 80 mg daily | 11.4 | false | MSI-H | 2026-03-15T05:35:59.877169+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_445273 | REC_0012050 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 29 | 5 | 71 | female | 2 | 19 | 6.1 | 4 | pembrolizumab 200 mg q3w | 11.1 | false | MSS | 2026-03-15T05:35:59.877396+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_287346 | REC_0012051 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 16.4 | 74 | female | 1 | 12 | 5.6 | 7 | osimertinib 80 mg daily | 9.9 | true | MSI-H | 2026-03-15T05:35:59.877625+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_692786 | REC_0012052 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 22 | 6.1 | 59 | female | 1 | 89 | 4.4 | 3 | carboplatin + paclitaxel + pembrolizumab | 15.1 | false | MSS | 2026-03-15T05:35:59.877902+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_321336 | REC_0012053 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 22 | 5.2 | 66 | female | 0 | 46 | 5.4 | 1 | pembrolizumab 200 mg q3w | 12 | false | MSS | 2026-03-15T05:35:59.878138+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_747938 | REC_0012054 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 26 | 10.1 | 74 | female | 2 | 11 | 3 | 0 | osimertinib 80 mg daily | 20.5 | false | MSI-H | 2026-03-15T05:35:59.878369+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_233762 | REC_0012055 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 27 | 14.8 | 65 | female | 0 | 8 | 5.7 | 7 | osimertinib 80 mg daily | 5.1 | true | MSS | 2026-03-15T05:35:59.878605+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_991603 | REC_0012056 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 13.8 | 74 | female | 1 | 9 | 4.2 | 6 | osimertinib 80 mg daily | 4.2 | true | MSS | 2026-03-15T05:35:59.878835+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_438999 | REC_0012057 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 26 | 11.6 | 66 | female | 0 | 18 | 3.2 | 1 | osimertinib 80 mg daily | 15.9 | false | MSI-H | 2026-03-15T05:35:59.879075+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_844460 | REC_0012058 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 31 | 14.1 | 60 | female | 0 | 15 | 4.8 | 5 | alectinib 600 mg BID | 13.1 | false | MSI-H | 2026-03-15T05:35:59.879309+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_138590 | REC_0012059 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 18 | 15.2 | 69 | female | 1 | 15 | 5.2 | 4 | entrectinib 600 mg daily | 5.1 | false | MSS | 2026-03-15T05:35:59.879547+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_452355 | REC_0012060 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 22 | 9.2 | 69 | male | 0 | 6 | 6.4 | 2 | sotorasib 960 mg daily | 34 | true | MSS | 2026-03-15T05:35:59.879781+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_272368 | REC_0012061 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 20 | 15.4 | 72 | female | 2 | 7 | 5.9 | 5 | sotorasib 960 mg daily | 4 | true | MSS | 2026-03-15T05:35:59.880011+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_543586 | REC_0012062 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 8.9 | 73 | female | 1 | 21 | 6.1 | 6 | sotorasib 960 mg daily | 10.3 | false | MSS | 2026-03-15T05:35:59.880267+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_668849 | REC_0012063 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 25 | 12.4 | 71 | male | 1 | 16 | 3.5 | 7 | pembrolizumab 200 mg q3w | 8.6 | false | MSS | 2026-03-15T05:35:59.880507+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_376361 | REC_0012064 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 30 | 9.1 | 83 | female | 1 | 19 | 5.5 | 2 | sotorasib 960 mg daily | 9.4 | false | MSS | 2026-03-15T05:35:59.880737+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_986525 | REC_0012065 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 12.1 | 55 | female | 0 | 27 | 5 | 3 | entrectinib 600 mg daily | 10.3 | false | MSI-H | 2026-03-15T05:35:59.881020+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_565426 | REC_0012066 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 21 | 8.7 | 65 | male | 1 | 12 | 7.4 | 4 | osimertinib 80 mg daily | 7.4 | false | MSS | 2026-03-15T05:35:59.881255+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_389473 | REC_0012067 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 20 | 10.1 | 63 | female | 1 | 15 | 5.2 | 8 | osimertinib 80 mg daily | 6.7 | false | MSS | 2026-03-15T05:35:59.881491+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_961686 | REC_0012068 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 29 | 10.4 | 77 | female | 3 | 7 | 4.2 | 1 | alectinib 600 mg BID | 19.9 | true | MSI-H | 2026-03-15T05:35:59.881723+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_556666 | REC_0012069 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 16.4 | 71 | male | 2 | 20 | 7 | 6 | alectinib 600 mg BID | 14.4 | true | MSI-H | 2026-03-15T05:35:59.881960+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_204226 | REC_0012070 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 19 | 10.4 | 73 | female | 1 | 12 | 4.3 | 7 | osimertinib 80 mg daily | 9 | true | MSS | 2026-03-15T05:35:59.882189+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_279552 | REC_0012071 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 24 | 10.4 | 64 | female | 0 | 19 | 3.8 | 1 | osimertinib 80 mg daily | 11 | true | MSS | 2026-03-15T05:35:59.882423+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_315879 | REC_0012072 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 34 | 11.7 | 77 | female | 3 | 16 | 6.6 | 5 | sotorasib 960 mg daily | 12.3 | false | MSI-H | 2026-03-15T05:35:59.882657+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_104138 | REC_0012073 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 19 | 14.2 | 62 | male | 1 | 10 | 3.7 | 7 | entrectinib 600 mg daily | 12.1 | false | MSI-H | 2026-03-15T05:35:59.882892+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_396051 | REC_0012074 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 15 | 7.6 | 70 | female | 2 | 32 | 2.7 | 6 | carboplatin + paclitaxel + pembrolizumab | 8.7 | false | MSS | 2026-03-15T05:35:59.883118+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_112686 | REC_0012075 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 14.5 | 64 | female | 1 | 10 | 5.5 | 4 | alectinib 600 mg BID | 4 | false | MSI-H | 2026-03-15T05:35:59.883356+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_173353 | REC_0012076 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 26 | 7.6 | 79 | female | 2 | 20 | 5.7 | 2 | pembrolizumab 200 mg q3w | 21 | true | MSS | 2026-03-15T05:35:59.883583+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_997660 | REC_0012077 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 16 | 12 | 72 | female | 2 | 7 | 4 | 1 | osimertinib 80 mg daily | 6.4 | false | MSI-H | 2026-03-15T05:35:59.883812+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_788818 | REC_0012078 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 26 | 6.8 | 69 | male | 1 | 15 | 5.3 | 8 | pembrolizumab 200 mg q3w | 14.3 | false | MSS | 2026-03-15T05:35:59.884116+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_259390 | REC_0012079 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 16 | 69 | female | 0 | 12 | 6 | 7 | osimertinib 80 mg daily | 8.9 | false | MSS | 2026-03-15T05:35:59.884362+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_902882 | REC_0012080 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 29 | 15.2 | 73 | female | 1 | 3 | 5.7 | 2 | alectinib 600 mg BID | 20 | false | MSI-H | 2026-03-15T05:35:59.884596+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_622090 | REC_0012081 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 23 | 9.1 | 48 | male | 0 | 17 | 4.6 | 2 | osimertinib 80 mg daily | 15 | true | MSS | 2026-03-15T05:35:59.884827+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_957945 | REC_0012082 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 26 | 14.3 | 68 | female | 0 | 14 | 5.9 | 1 | sotorasib 960 mg daily | 19.2 | false | MSI-H | 2026-03-15T05:35:59.885055+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_879862 | REC_0012083 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 12 | 4.2 | 68 | female | 1 | 12 | 6.4 | 3 | pembrolizumab 200 mg q3w | 15.5 | false | MSS | 2026-03-15T05:35:59.885284+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_178294 | REC_0012084 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 13.3 | 66 | female | 1 | 17 | 5.3 | 7 | sotorasib 960 mg daily | 6.7 | false | MSS | 2026-03-15T05:35:59.885515+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_559666 | REC_0012085 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 25 | 11.6 | 54 | male | 0 | 13 | 5.5 | 2 | osimertinib 80 mg daily | 16.2 | false | MSS | 2026-03-15T05:35:59.885754+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_887053 | REC_0012086 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 29 | 10.2 | 74 | female | 2 | 17 | 5 | 1 | sotorasib 960 mg daily | 16.1 | false | MSS | 2026-03-15T05:35:59.885989+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_505529 | REC_0012087 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 18 | 6.7 | 61 | female | 0 | 16 | 5.7 | 1 | entrectinib 600 mg daily | 26.2 | true | MSS | 2026-03-15T05:35:59.886220+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_406828 | REC_0012088 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 17 | 7.7 | 74 | female | 1 | 20 | 6.4 | 5 | carboplatin + paclitaxel + pembrolizumab | 11.3 | false | MSS | 2026-03-15T05:35:59.886450+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_936445 | REC_0012089 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 6.9 | 70 | female | 1 | 52 | 5.9 | 3 | carboplatin + paclitaxel + pembrolizumab | 8.2 | false | MSS | 2026-03-15T05:35:59.886679+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_205394 | REC_0012090 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 25 | 3.8 | 68 | female | 0 | 31 | 6 | 2 | carboplatin + paclitaxel + pembrolizumab | 13.3 | false | MSS | 2026-03-15T05:35:59.886907+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_249565 | REC_0012091 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 2.7 | 46 | male | 0 | 14 | 6.5 | 7 | alectinib 600 mg BID | 5 | true | MSS | 2026-03-15T05:35:59.887186+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_778505 | REC_0012092 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 15 | 19.8 | 76 | female | 3 | 19 | 4.4 | 2 | osimertinib 80 mg daily | 10.5 | true | MSS | 2026-03-15T05:35:59.887419+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_615828 | REC_0012093 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 30 | 13.4 | 63 | female | 1 | 14 | 4.8 | 1 | osimertinib 80 mg daily | 21.7 | false | MSI-H | 2026-03-15T05:35:59.887655+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_207507 | REC_0012094 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 9 | 49 | male | 0 | 7 | 6.3 | 5 | entrectinib 600 mg daily | 4.4 | false | MSS | 2026-03-15T05:35:59.887884+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_237156 | REC_0012095 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 22 | 6.5 | 63 | female | 0 | 19 | 5.4 | 5 | pembrolizumab 200 mg q3w | 4 | true | MSS | 2026-03-15T05:35:59.888162+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_763840 | REC_0012096 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 16.5 | 73 | female | 3 | 18 | 5.2 | 5 | alectinib 600 mg BID | 12.3 | false | MSS | 2026-03-15T05:35:59.888411+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_824579 | REC_0012097 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 20 | 16.6 | 67 | female | 1 | 20 | 5.9 | 5 | alectinib 600 mg BID | 7.2 | true | MSS | 2026-03-15T05:35:59.888648+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_508278 | REC_0012098 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 14.2 | 74 | female | 1 | 12 | 5.5 | 7 | sotorasib 960 mg daily | 4.4 | true | MSS | 2026-03-15T05:35:59.888880+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_718184 | REC_0012099 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 20 | 18.9 | 72 | female | 2 | 11 | 7.2 | 5 | alectinib 600 mg BID | 11.3 | false | MSI-H | 2026-03-15T05:35:59.889117+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_702139 | REC_0012100 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 7 | 76 | male | 2 | 19 | 4 | 7 | alectinib 600 mg BID | 7 | false | MSS | 2026-03-15T05:35:59.889350+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.